Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Velnacrine SCHEMBL7193446 | 0.91 | TSHR (0.83) | CYP1A2CYP2C9TSHRALDH1A1NR3C1 | |
| Velnacrine SCHEMBL50846 | 0.91 | TSHR (0.83) | CYP1A2CYP2C9TSHRALDH1A1NR3C1 | |
| Velnacrine SCHEMBL637476 | 0.91 | TSHR (0.83) | CYP1A2CYP2C9TSHRALDH1A1NR3C1 | |
| Velnacrine SCHEMBL9634108 | 0.90 | TSHR (0.81) | CYP1A2CYP2C9TSHRALDH1A1NR3C1 | |
| Velnacrine SCHEMBL14814443 | 0.88 | TSHR (0.77) | CYP1A2CYP2C9TSHRALDH1A1NR3C1 | |
| SCHEMBL3807927 | 0.84 | CYP1A2 (0.72) | CYP1A2CYP2C9TSHRALDH1A1NR3C1 | |
| Velnacrine SCHEMBL6129239 | 0.83 | TSHR (0.69) | CYP1A2CYP2C9TSHRALDH1A1NR3C1 | |
| Hydrochloric Acid SCHEMBL3242591 | 0.82 | TSHR (0.70) | CYP1A2CYP2C9TSHRALDH1A1NR3C1 | |
| SCHEMBL27937060 | 0.82 | ACHE (0.70) | CYP1A2CYP2C9TSHRALDH1A1NR3C1 | |
| SCHEMBL9685394 | 0.82 | ACHE (0.69) | CYP1A2CYP2C9TSHRALDH1A1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 676 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635489-A1 | COMPOSITION FOR PREVENTING OR TREATING SIDE EFFECTS OF CHOLINESTERASE INHIBITORS | Dr.Noah Biotech Inc. (KR) | 2025-10-22 | — | — | EP | claimed |
| EP-4473964-A1 | COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE | Dr.Noah Biotech Inc. (KR) | 2024-12-11 | — | — | EP | claimed |
| US-20240294986-A1 | PRECISION MEDICINE FOR SCHIZOPHRENIA AND PSYCHOTIC DISORDERS: OBJECTIVE ASSESSMENT, RISK PREDICTION, PHARMACOGENOMICS, AND REPURPOSED DRUGS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2024-09-05 | — | — | US | claimed |
| WO-2024128473-A1 | COMPOSITION FOR PREVENTING OR TREATING SIDE EFFECTS OF CHOLINESTERASE INHIBITORS | 닥터노아바이오텍 주식회사 | 2024-06-20 | — | — | WO | claimed |
| US-20240148711-A1 | COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE | DR.NOAH BIOTECH INC. (KR) | 2024-05-09 | — | — | US | claimed |
| EP-4355423-A1 | PRECISION MEDICINE FOR SCHIZOPHRENIA AND PSYCHOTIC DISORDERS: OBJECTIVE ASSESSMENT, RISK PREDICTION, PHARMACOGENOMICS, AND REPURPOSED DRUGS | Indiana University Research and Technology Corporation (US) | 2024-04-24 | — | — | EP | claimed |
| US-20240066017-A1 | PREVENTION OR TREATMENT OF BRAIN DISEASE AND ADVERSE EFFECTS OF CHOLINESTERASE INHIBITORS | DR. NOAH BIOTECH INC. (KR) | 2024-02-29 | — | — | US | claimed |
| EP-4285901-A1 | COMPOSITE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF BRAIN DISEASE, COMPRISING CHOLINESTERASE INHIBITOR AND ANTIOXIDANT | Dr.Noah Biotech Inc. (KR) | 2023-12-06 | — | — | EP | claimed |
| WO-2023149682-A1 | COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE | 닥터노아바이오텍 주식회사 | 2023-08-10 | — | — | WO | claimed |
| US-20220403469-A1 | Precision Medicine for Schizophrenia and Psychotic Disorders: Objective Assessment, Risk Prediction, Pharmacogenomics, and Repurposed Drugs | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-12-22 | — | — | US | claimed |
| EP-1030671-A1 | COMBINATION OF ACTIVE PRINCIPLES, IN PARTICULAR OF TETRAHYDROPYRIDINS AND ACETYLCHOLINESTERASE INHIBITING AGENTS, FOR TREATING SENILE DEMENTIA SUCH AS ALZHEIMER DEMENTIA | SANOFI-SYNTHELABO (FR) | 2000-08-30 | — | — | EP | claimed |
| WO-2000025821-A1 | METHOD OF TREATING AND DIAGNOSING RESTLESS LEGS SYNDROME AND CORRESPONDING MEANS | HEDNER JAN (SE) | 2000-05-11 | — | — | WO | claimed |
| US-6034117-A | Methods of treating and diagnosing sleep disordered breathing and means for carrying out the method | PHARMAPNEA AB (SE) | 2000-03-07 | — | — | US | claimed |
| WO-1999047131-A2 | COMBINATION OF A GABA-A ALPHA 5 INVERSE AGONIST AND AN ACETYLCHOLINESTERASE INHIBITOR | MERCK SHARP & DOHME LIMITED (GB) | 1999-09-23 | — | — | WO | claimed |
| WO-1999025363-A1 | COMBINATION OF ACTIVE PRINCIPLES, IN PARTICULAR OF TETRAHYDROPYRIDINS AND ACETYLCHOLINESTERASE INHIBITING AGENTS, FOR TREATING SENILE DEMENTIA SUCH AS ALZHEIMER DEMENTIA | SANOFI-SYNTHELABO (FR) | 1999-05-27 | — | — | WO | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| EP-0179383-B1 | 9-AMINO-1,2,3,4-TETRAHYDROACRIDIN-1-OL AND RELATED COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-05-29 | — | — | EP | claimed |
| US-4631286-A | MEMORY ENHANCERS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1986-12-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148711-A1 | COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE | ACHE, BACE1, CHRNB4 | CYP1A2 1974/4885CYP2C9 2868/4885TSHR 4467/4885 |
| US-20240066017-A1 | PREVENTION OR TREATMENT OF BRAIN DISEASE AND ADVERSE EFFECTS OF CHOLINESTERASE INHIBITORS | ACHE, BCHE, CHAT | CYP1A2 950/4885CYP2C9 996/4885TSHR 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.